XT
CADL icon

XTX Topco’s Candel Therapeutics CADL Stock Holding History

XTX Topco’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$214K Buy
43,763
+19,987
+84% +$109K ﹤0.01% 2793
2025
Q4 		$134K Buy
+23,776
New +$128K ﹤0.01% 2546
2025
Q3 		– Sell
-74,629
Closed -$378K – 2619
2025
Q2 		$378K Buy
+74,629
New +$384K 0.02% 1289

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

XTX Topco's CADL Position: Q1 2026 in Review

XTX Topco increased its Candel Therapeutics (CADL) stake by 84% in Q1 2026, buying an estimated $109K and bringing the position to 43,763 shares worth $214K. The position accounts for ﹤0.01% of the portfolio, ranked #2793.

XTX Topco first reported a position in CADL in Q2 2025 and has held it in 3 quarters since. The position peaked at $378K in Q2 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • XTX Topco held 43,763 shares of Candel Therapeutics worth $214K as of Q1 2026.
  • XTX Topco bought 19,987 Candel Therapeutics shares in Q1 2026, an estimated $109K.
  • Candel Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q1 2026, its #2793 holding.
  • XTX Topco first reported a position in Candel Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • XTX Topco's Candel Therapeutics position peaked at $378K in Q2 2025.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.